May 7, 2026—Roche has entered into a definitive merger agreement to acquire PathAI, extending a partnership that began in 2021 and expanded in 2024 to develop AI-based companion diagnostic algorithms. Roche will pay a purchase price of $750 million upfront and additional milestone payments of up to $300 million.
“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” Matt Sause, CEO of Roche Diagnostics, said in a press release. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”
PathAI’s AISight image management system software interface integrates advanced analysis and workflow capabilities within the digital pathology laboratory; Roche intends to scale this solution worldwide. PathAI’s strength in AI-driven solutions, including clinical trial support and translational research, will complement Roche’s expertise in companion diagnostics, according to the release. Combining these capabilities will help the discovery of new biomarkers, potential drug targets, and novel diagnostic tools.
The closing is subject to customary closing conditions, including antitrust and regulatory approvals, and is expected in the second half of the year. The acquired entity will become part of Roche’s diagnostics division.